Axa S.A. Sells 1,478 Shares of Penumbra, Inc. (NYSE:PEN)

AXA S.A. reduced its position in Penumbra, Inc. (NYSE:PEN - Free Report) by 1.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 109,641 shares of the company's stock after selling 1,478 shares during the quarter. AXA S.A. owned approximately 0.29% of Penumbra worth $26,038,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of PEN. UMB Bank n.a. boosted its position in Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after acquiring an additional 70 shares during the last quarter. Hurley Capital LLC acquired a new stake in Penumbra during the fourth quarter worth approximately $56,000. Huntington National Bank grew its stake in Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after purchasing an additional 154 shares during the period. Mather Group LLC. increased its holdings in Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock worth $73,000 after purchasing an additional 208 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in Penumbra by 25.0% in the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock valued at $89,000 after buying an additional 75 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Stock Up 3.0 %

PEN traded up $8.52 during mid-day trading on Friday, reaching $297.25. 972,988 shares of the stock were exchanged, compared to its average volume of 426,873. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The stock has a market capitalization of $11.51 billion, a PE ratio of 874.26, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The company has a 50 day moving average price of $277.75 and a two-hundred day moving average price of $260.95.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business had revenue of $324.14 million for the quarter, compared to analysts' expectations of $315.72 million. During the same period in the previous year, the company earned $0.41 earnings per share. The firm's revenue for the quarter was up 16.3% compared to the same quarter last year. As a group, research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analyst Weigh In

PEN has been the subject of several recent analyst reports. Truist Financial raised their price objective on shares of Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. BTIG Research reaffirmed a "buy" rating on shares of Penumbra in a research note on Thursday, April 24th. Stifel Nicolaus set a $318.00 price objective on shares of Penumbra and gave the stock a "buy" rating in a research report on Thursday, April 24th. Piper Sandler restated an "overweight" rating and issued a $330.00 target price (up from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company upped their price target on Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Insider Activity

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $300.01, for a total value of $180,006.00. Following the transaction, the executive vice president now owns 66,159 shares of the company's stock, valued at approximately $19,848,361.59. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Adam Elsesser sold 61,600 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total value of $17,469,144.00. Following the completion of the transaction, the chief executive officer now owns 16,376 shares of the company's stock, valued at $4,644,069.84. This trade represents a 79.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 159,096 shares of company stock valued at $44,959,983 over the last three months. Corporate insiders own 5.00% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.